IceCure Medical Falls 3% as Benzinga Flags Two Equities for Active Monitoring
IceCure Medical Ltd. (NASDAQ: ICCM) shed 3.13% to $6.80 on June 26, even as the Caesarea, Israel-based cryoablation device maker carried a market capitalization of $572.57 million and a 52-week range spanning $2.12 to $42. Benzinga named IceCure and Carbon Revolution PLC as equities its team would be closely watching.
IceCure Medical Ltd. (NASDAQ: ICCM) shed 3.13% to $6.80 on June 26, even as the Caesarea, Israel-based cryoablation device maker carried a market capitalization of $572.57 million and a 52-week range spanning $2.12 to $42. Benzinga named IceCure and Carbon Revolution PLC as equities its team would be closely watching.
IceCure Medical: Device Maker With a Wide Price Range
Incorporated in 2006 and headquartered in Caesarea, Israel, IceCure Medical is a commercial-stage company that researches, develops and sells cryoablation systems — equipment that destroys tumors by freezing — across urology, oncology, dermatology, gynecology, general surgery, thoracic surgery and proctology. Shares outstanding totaled 84.20 million against a total float of 47.60 million, a gap that leaves a material portion of the company outside freely traded hands. The 52-week spread from $2.12 to $42 signals a stock prone to large moves in either direction.
Carbon Revolution: No Price Data Reported
Carbon Revolution PLC, founded in 2004 and headquartered in Waum Ponds, Australia, designs, manufactures and markets single-piece carbon fiber wheels to the automotive industry. As of the June 26 snapshot at 10:20 a.m., the company returned no price, volume or market capitalization data.
The Screening Method Behind the List
Benzinga contributor Zaheer Anwari describes a three-filter process: tracking what share of stocks trade above their 200-day simple moving average, identifying equities printing new all-time highs, and weighing performance history. Anwari identifies the weekly 200-day moving average as a key structural floor, pointing to instances where it held in 2011, 2016 and 2018. He ties the S&P 500's gain of more than 10% in the first six months of 2023 partly to that level acting as support.
The framework explicitly favors trend-following over value investing, with Anwari citing sector rotation as the mechanism: health care and energy led in 2022, a year in which MCK gained roughly 50% while the S&P 500 fell 25% and PYPL dropped 80%. Anwari's suggested holding window runs 12 to 24 months before rebalancing, and he recommends waiting for the S&P 500 to confirm a bull trend above its daily 200-day moving average before committing new capital.